Filter articles using the following links

GenSight Biologics obtains a €7m non-dilutive loan and renegotiates the bond agreement with Kreos Capital extending runway to mid-2021

GenSight Biologics reports sustained efficacy and safety among LHON patients three years after LUMEVOQ® treatment

GenSight Biologics to Host LUMEVOQ® Key Opinion Leader Call on July 9, 2020

KOL Call on LUMEVOQ® for the Treatment of Leber Hereditary Optic Neuropathy (LHON)

BIO 2020, San Diego (CA), US – Digital

2020 ARVO Annual Meeting, Baltimore (MD), US – cancelled

ASGCT 23rd Annual Meeting, Boston (MA), USA – Virtual Format

GenSight Biologics will hold its General Meeting on April 29, 2020 behind closed doors

2020 AAN Annual Meeting, Toronto, Canada – canceled due to COVID-19

GenSight Biologics Reports Cash Position as of March 31, 2020 and Provides Operational Update